furazolidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1257 67-45-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • furazolidone
  • diafuron
  • furaxone
  • furazol
  • furazolidinone
  • furazolidon
  • furazon
  • furidon
  • nitrofurazolidone
  • nitrofuroxon
  • furoxone
A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
  • Molecular weight: 225.16
  • Formula: C8H7N3O5
  • CLOGP: -0.04
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 0
  • TPSA: 98.18
  • ALOGS: -2.79
  • ROTB: 3
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 0.04 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,STK33,SYK,TEK,TTK 41
kinase-selectivity-class AXL,BRAF,CDK9,DDR1,DYRK1B,GRK2,GSK3B,IRAK1,MAP2K6,MAP3K14,MAPK1,MAPK7,MARK4,MET,PRKDC,STK33,SYK,TEK,TTK,UHMK1 20
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Jan. 20, 1958 FDA SHIRE

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 358.12 222.49 118 6671 13338 42601208
Blood phosphorus increased 346.06 222.49 113 6676 12412 42602134
Myasthenia gravis 325.61 222.49 115 6674 16022 42598524
Appendicitis 319.75 222.49 121 6668 20492 42594054
Hyperphosphataemia 274.99 222.49 96 6693 12908 42601638
Ventricular fibrillation 265.64 222.49 118 6671 30005 42584541
Stress 254.26 222.49 129 6660 44083 42570463
Analgesic therapy 234.56 222.49 72 6717 6452 42608094
Cardiogenic shock 234.52 222.49 114 6675 35526 42579020
Blood uric acid increased 229.22 222.49 88 6701 15459 42599087
Hypophosphataemia 227.12 222.49 95 6694 20850 42593696
Sleep disorder therapy 226.46 222.49 71 6718 6823 42607723
Drug therapy 223.40 222.49 69 6720 6311 42608235
Incorrect route of product administration 223.20 222.49 98 6691 24207 42590339
Bacterial infection 222.83 222.49 102 6687 27777 42586769

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 485.07 172.00 125 7357 14130 110567687
Blood phosphorus increased 444.52 172.00 120 7362 16220 110565597
Myasthenia gravis 420.74 172.00 122 7360 21389 110560428
Appendicitis 412.17 172.00 128 7354 28336 110553481
Hyperphosphataemia 365.59 172.00 103 7379 16278 110565539
Ventricular fibrillation 353.86 172.00 125 7357 41188 110540629
Analgesic therapy 323.00 172.00 79 7403 7205 110574612
Sleep disorder therapy 315.95 172.00 78 7404 7393 110574424
Drug therapy 307.72 172.00 76 7406 7215 110574602
Blood uric acid increased 303.94 172.00 95 7387 21434 110560383
Cardiogenic shock 300.06 172.00 121 7361 57217 110524600
Hypophosphataemia 290.18 172.00 102 7380 33080 110548737
Bacterial infection 282.39 172.00 109 7373 45927 110535890
Stress 273.27 172.00 136 7346 105212 110476605
Ascites 265.17 172.00 128 7354 92680 110489137
Neuralgia 262.92 172.00 105 7377 48373 110533444
Multiple organ dysfunction syndrome 239.85 172.00 141 7341 151569 110430248
Incorrect route of product administration 231.50 172.00 104 7378 63957 110517860
Antacid therapy 230.56 172.00 57 7425 5427 110576390
Anticoagulant therapy 216.73 172.00 54 7428 5307 110576510
Activated partial thromboplastin time prolonged 211.82 172.00 73 7409 22295 110559522
Diabetes mellitus 207.69 172.00 111 7371 99270 110482547
Iron deficiency 205.30 172.00 68 7414 18408 110563409
Abdominal distension 196.61 172.00 131 7351 174972 110406845
Thrombosis 192.96 172.00 109 7373 108553 110473264
Hyponatraemia 191.07 172.00 140 7342 217513 110364304
End stage renal disease 187.60 172.00 66 7416 21407 110560410
Chronic obstructive pulmonary disease 179.08 172.00 104 7378 109054 110472763

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G01AX06 GENITO URINARY SYSTEM AND SEX HORMONES
GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
Other antiinfectives and antiseptics
ATC P01AB51 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES
Nitroimidazole derivatives
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000891 Anti-Infective Agents, Local
MeSH PA D000892 Anti-Infective Agents, Urinary
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents
MeSH PA D000994 Antitrichomonal Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D008996 Monoamine Oxidase Inhibitors
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:38623 EC 1.4.3.4 (monoamine oxidase) inhibitor
CHEBI has role CHEBI:50685 antitrichomonal drug

Related Drugs by ATC class:

G01AX Other antiinfectives and antiseptics 10 drugs
ciclopiroxclodantoinhexetidineinosinemethylrosanilinenifurateloctenidinepolicresulenpovidone-iodineprotiofate
P01AB Nitroimidazole derivatives 7 drugs
azanidazolemetronidazolenimorazoleornidazolepropenidazolesecnidazoletinidazole

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Anemia due to enzyme deficiency contraindication 111577008
Deficiency of glucose-6-phosphate dehydrogenase contraindication 124134002 DOID:2862




🐶 Veterinary Drug Use

SpeciesUseRelation
Dogs Prevention of bacterial infection of superficial wounds, abrasions, lacerations, and pyogenic dermatitis Indication
Horses Prevention of bacterial infection of superficial wounds, abrasions, lacerations, and following firing (heat or electrocautery) Indication

🐶 Veterinary products

ProductApplicantIngredients
Furox Aerosol Powder, Topazone Aerosol Powder Kinetic Technologies LLC 1
Furall Farnam Companies Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.72 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4018877 VUID
N0000147172 NUI
D00830 KEGG_DRUG
4018877 VANDF
C0016855 UMLSCUI
CHEBI:5195 CHEBI
FUR PDB_CHEM_ID
CHEMBL1103 ChEMBL_ID
DB00614 DRUGBANK_ID
D005664 MESH_DESCRIPTOR_UI
5323714 PUBCHEM_CID
12343 IUPHAR_LIGAND_ID
273 INN_ID
5J9CPU3RE0 UNII
224944 RXNORM
416 MMSL
4768 MMSL
d00243 MMSL
002855 NDDF
416556006 SNOMEDCT_US
91314000 SNOMEDCT_US

Pharmaceutical products:

None